Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology - Wikidata - awgldk - TriplyDB

Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

http://www.wikidata.org/entity/Q22241657

about

An update on the diagnosis and treatment of Parkinson disease Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.DRUM-PD: The use of a drum circle to improve the symptoms and signs of Parkinson's disease (PD)Deep brain stimulation of caudal zona incerta and subthalamic nucleus in patients with Parkinson's disease: effects on voice intensity Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.Current clinical practice for Parkinson's disease among Chinese physicians, general neurologists and movement disorders specialists: a national survey.Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.Pleurotus giganteus (Berk.) Karunarathna & K.D. Hyde: Nutritional value and in vitro neurite outgrowth activity in rat pheochromocytoma cells.Seniors with Parkinson's disease: initial medical treatment.Two-year exercise program improves physical function in Parkinson's disease: the PRET-PD randomized clinical trial.Trends in inpatient antiparkinson drug use in the USA, 2001-2012.Can the disease course in Parkinson's disease be slowed?Promoting exercise in Parkinson's disease through community-based participatory research.Parkinson's Disease and Its Management: Part 3: Nondopaminergic and Nonpharmacological Treatment Options.The quantity and quality of complementary and alternative medicine clinical practice guidelines on herbal medicines, acupuncture and spinal manipulation: systematic review and assessment using AGREE II The Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate.Pharmacotherapy for Parkinson's disease.Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts.Treatment options for non-motor symptoms in late-stage Parkinson's disease.Protection against Parkinson's disease progression: clinical experience.Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study Targets for neuroprotection in Parkinson's disease Tai Ji Quan Exercise for People with Parkinson's Disease and Other Neurodegenerative Movement Disorders Micronutrients and Risk of Parkinson's Disease: A Systematic Review.Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition.Olfaction as a biomarker in Parkinson's disease.Parkinson's disease--the continuing search for biomarkers.Physical, occupational, speech and swallowing therapies and physical exercise in Parkinson's disease.Balance and falls in Parkinson's disease: a meta-analysis of the effect of exercise and motor training.The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.Cheaper, simpler, and better: tips for treating seniors with Parkinson disease.Exercise and motor training in people with Parkinson's disease: a systematic review of participant characteristics, intervention delivery, retention rates, adherence, and adverse events in clinical trials.Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease.The timing of deep brain stimulation for Parkinson disease in the UK from 1997 to 2012.Opicapone for the treatment of Parkinson's disease.The impact of Tai Chi and Qigong mind-body exercises on motor and non-motor function and quality of life in Parkinson's disease: A systematic review and meta-analysis.Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review.

P2860

Q30243899-7CF60FD3-DB3C-427D-A113-ED281F12C728 Q30357397-6A6DDC47-53F9-4C4A-91B4-DE544FC83E56 Q30389730-6B1C3D6D-1A68-4AAA-9899-4252417A725B Q30473590-00C6850F-25ED-4988-838D-6E8E7AEADDD4 Q30477266-48046574-8479-43AF-9678-F1B6C8DF4239 Q31108322-5ADD9995-480A-4C4A-87D2-CE1A978892CE Q33828847-50F3A6FF-0A27-44FA-8129-0AC92F5FC481 Q34152355-D1D67776-D767-42E6-A275-44A8BEB6BAAB Q34343765-2F1A2A87-5272-4F9E-996E-A05223F55542 Q34508143-E91220B5-0F67-4021-BF94-92791E2822CC Q34772565-36A09BF9-7AB4-4F7E-8F71-0B04B40E5CC3 Q35847512-CF7F727A-F1A3-4DD1-ADE2-11846F43736F Q35865171-4965B2C9-9070-479E-9725-16D9244064F9 Q35915858-BE8656A5-8F90-4D84-BB4E-479361D6B877 Q36164724-2D631803-A70B-4DD5-AE81-D1351501A065 Q36177578-7536A6B4-4A89-4AEA-9FE4-9CD3702900EA Q36241835-E25E0173-911C-42EC-ADE2-5EEE39F1F5AA Q37016031-E0320A5F-C295-4BCA-A1C4-B2EAE63775CC Q37016034-491B20BC-86EA-4FAC-B56E-947FCDA5727B Q37036351-83D29662-E97D-4754-86E5-3238B8FDB4C8 Q37098986-4C33CEF4-4168-4601-902A-B08D591E9255 Q37131239-3DA2AD43-DD7E-4291-8066-E9EAA39B1C4E Q37265848-89B57124-1CD9-4733-8995-E7D89AEFBF75 Q37302453-DC53A4E5-FFAC-48EA-B04A-FC1DEECB6A39 Q37307292-49565D2C-23A1-4191-BF8A-2EFDADF88EE4 Q37429643-0E8B20F2-CA12-461C-90C4-4178756A3586 Q37724555-EE02C39B-3EF6-4B14-8AB1-61D91B5E2B6E Q37779428-EDB2F6BB-988A-4746-AD9D-AA7068B80E64 Q37800097-669AA33C-26F1-4CA7-8CE3-88A6F70E1074 Q37834648-95FAA907-AADC-4F84-87EC-0925C9B94A34 Q37861015-F98A5F6C-8954-4E44-B91A-70660C6546AC Q37889787-EB49FEC2-7111-4640-AF04-28C9177A9D89 Q37948713-49B2E976-76D8-45FD-A2AE-A7A7FDAB8F9F Q37963796-3E42733F-193A-4923-80BD-8EFEB9A9456C Q37970687-FA070661-7E0F-431D-9F51-C19FA3C3A4A7 Q38250185-560A5243-8F42-429A-AD56-6C2E01D80417 Q38587027-6725A7EE-9AB1-4E48-93E8-FF11A5047541 Q38943872-EBD9C0B2-74A2-467A-8E98-D5BE06885060 Q39365181-F06A2929-2B58-48B0-BB00-9B71AEBF9EEC Q39428788-10FF6725-C497-436A-BA71-96F5B18AA3D6

P2860

Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

http://www.wikidata.org/entity/Q22241657

description

2006 nî lūn-bûn

@nan

2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Practice Parameter: Neuroprote ...... American Academy of Neurology

@ast

Practice Parameter: Neuroprote ...... American Academy of Neurology

@en

Practice Parameter: Neuroprote ...... American Academy of Neurology

@en-gb

Practice Parameter: Neuroprote ...... American Academy of Neurology

@nl

type

label

Practice Parameter: Neuroprote ...... American Academy of Neurology

@ast

Practice Parameter: Neuroprote ...... American Academy of Neurology

@en

Practice Parameter: Neuroprote ...... American Academy of Neurology

@en-gb

Practice Parameter: Neuroprote ...... American Academy of Neurology

@nl

altLabel

Practice Parameter: neuroprote ...... American Academy of Neurology

@en

prefLabel

Practice Parameter: Neuroprote ...... American Academy of Neurology

@ast

Practice Parameter: Neuroprote ...... American Academy of Neurology

@en

Practice Parameter: Neuroprote ...... American Academy of Neurology

@en-gb

Practice Parameter: Neuroprote ...... American Academy of Neurology

@nl

P1433

Q22241657-BA45AB39-AB14-4B27-BEC8-97D8977AF0E9

P1476

Q22241657-A4315026-7A72-49CC-9B59-65B5BAEFD548

P2093

Q22241657-061CB211-DB7D-4F2D-9F31-66A98E6696C0

Q22241657-51B3E52D-0E93-44E9-8A07-6049AC3A52C1

Q22241657-5C94EF96-305E-43CF-83B2-01E761936550

Q22241657-9AA1FC60-0C8E-4DE7-B7B2-FAF3C375D043

Q22241657-A4F6E14D-382B-4DBA-B605-A260771F2348

Q22241657-AD19E09A-0596-400A-8F4A-48CAEA405DE1

P304

Q22241657-CCC07A79-6B6A-4A9F-8449-C777BA4878DA

P31

Q22241657-591F3CB0-599C-4109-9263-32844B1D7FE7

P3181

Q22241657-B283B7A1-D2B3-4562-AAF7-6E99F5F98985

P356

Q22241657-CEA94750-2369-4D3D-925A-3A4DFA426E33

P407

Q22241657-9E45D471-A5F9-400F-9286-16DC16E535BF

P433

Q22241657-BD8936CB-B811-4B2A-AC69-62CB9374C7A6

P478

Q22241657-B4E1EF58-1CEF-424D-B654-F2B248471585

P577

Q22241657-40E48DF2-2F3D-4DDA-B60F-9AD3249606E0

P5875

Q22241657-1E23F46E-BF4B-451D-9A9C-29523EDBA587

P698

Q22241657-EA1679A6-2CF4-473A-ADA6-AE2D9E96AF5F

P921

Q22241657-A71D5883-4917-4CF8-AB3C-65DBB221231D

P3181

P356

01.WNL.0000206363.57955.1B

P1433

P1476

Practice Parameter: Neuroprote ...... American Academy of Neurology

@en

P2093

G. Gronseth

http://www.w3.org/2001/XMLSchema#string

J. Perlmutter

http://www.w3.org/2001/XMLSchema#string

O. Suchowersky

http://www.w3.org/2001/XMLSchema#string

S. Reich

http://www.w3.org/2001/XMLSchema#string

T. Zesiewicz

http://www.w3.org/2001/XMLSchema#string

W. J. Weiner

http://www.w3.org/2001/XMLSchema#string

P304

976-982

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2748017

http://www.w3.org/2001/XMLSchema#string

P356

10.1212/01.WNL.0000206363.57955.1B

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7172974

http://www.w3.org/2001/XMLSchema#string

P698

16606908

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease